TY - JOUR
T1 - Integrin alpha 2 is associated with tumor progression and postoperative recurrence in non-small cell lung cancer
AU - Matsumoto, Yoko
AU - Kage, Hidenori
AU - Morota, Mizuki
AU - Zokumasu, Koichi
AU - Ando, Takahiro
AU - Maemura, Keita
AU - Watanabe, Kousuke
AU - Kawakami, Masanori
AU - Hinata, Munetoshi
AU - Ushiku, Tetsuo
AU - Nakajima, Jun
AU - Nagase, Takahide
N1 - Publisher Copyright:
© The Author(s) 2022. Published by Oxford University Press. All rights reserved.
PY - 2023/1/1
Y1 - 2023/1/1
N2 - Background: Integrins are transmembrane proteins that mediate cell adhesion to extracellular matrix. Whereas expression of integrin alpha 2 is associated with motility, invasiveness and cellular differentiation in various tumors, the role of integrin alpha 2 in lung cancer has not been studied in detail. The aim of this study was to determine whether and how aberrant integrin alpha 2 expression in non-small cell lung cancer leads to different outcomes. Methods: We measured expression of integrin alpha 2 by quantitative polymerase chain reaction in 100 samples collected from non-small cell lung cancer patients who had undergone surgical resection. We assigned patients to high and low expression groups and analyzed survival. Cellular morphology, adhesion, proliferation, migration and invasion were examined in human lung cancer cell lines. Results: Among 100 cases, 41 were female, with a median age of 71 years. High expression of integrin alpha 2 in non-small cell lung cancer was associated with lower recurrence-free survival (P = 0.004). Overexpression of integrin alpha 2 in cell lines had no effect on cell proliferation or invasion but resulted in increased cell size (1416 μm2 versus 470 μm2 in H522 cells, P < 0.001; 1822 μm2 versus 1029 μm2 in H661 cells, P = 0.02), adhesion (P < 0.001 in H522 and H661 cells) and migration (gap area filled was 71% versus 36% in H522 cells, P < 0.001; 57% versus 26% in H661 cells, P = 0.001). These changes were suppressed by E7820, an inhibitor of integrin alpha 2. Conclusions: Integrin alpha 2 may play a significant role in lung cancer adhesion and migration, and may lead to a higher risk of recurrence.
AB - Background: Integrins are transmembrane proteins that mediate cell adhesion to extracellular matrix. Whereas expression of integrin alpha 2 is associated with motility, invasiveness and cellular differentiation in various tumors, the role of integrin alpha 2 in lung cancer has not been studied in detail. The aim of this study was to determine whether and how aberrant integrin alpha 2 expression in non-small cell lung cancer leads to different outcomes. Methods: We measured expression of integrin alpha 2 by quantitative polymerase chain reaction in 100 samples collected from non-small cell lung cancer patients who had undergone surgical resection. We assigned patients to high and low expression groups and analyzed survival. Cellular morphology, adhesion, proliferation, migration and invasion were examined in human lung cancer cell lines. Results: Among 100 cases, 41 were female, with a median age of 71 years. High expression of integrin alpha 2 in non-small cell lung cancer was associated with lower recurrence-free survival (P = 0.004). Overexpression of integrin alpha 2 in cell lines had no effect on cell proliferation or invasion but resulted in increased cell size (1416 μm2 versus 470 μm2 in H522 cells, P < 0.001; 1822 μm2 versus 1029 μm2 in H661 cells, P = 0.02), adhesion (P < 0.001 in H522 and H661 cells) and migration (gap area filled was 71% versus 36% in H522 cells, P < 0.001; 57% versus 26% in H661 cells, P = 0.001). These changes were suppressed by E7820, an inhibitor of integrin alpha 2. Conclusions: Integrin alpha 2 may play a significant role in lung cancer adhesion and migration, and may lead to a higher risk of recurrence.
KW - adhesion
KW - integrin alpha 2
KW - migration
KW - non–small cell lung cancer
KW - postoperative recurrence
UR - http://www.scopus.com/inward/record.url?scp=85145955618&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145955618&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyac148
DO - 10.1093/jjco/hyac148
M3 - Article
C2 - 36151049
AN - SCOPUS:85145955618
SN - 0368-2811
VL - 53
SP - 63
EP - 73
JO - Japanese journal of clinical oncology
JF - Japanese journal of clinical oncology
IS - 1
ER -